Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
The Pharmaceutical Market: Netherlands
Management Report
Published: January 2010
Pages: 54
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 595.00 Buy Now!
Research from: Espicom
Sector: Prescription Medicines
Espicom’s in-depth pharmaceutical market reports are ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
In 2009, the Dutch economy contracted by 4.1%, according to figures from the Economist Intelligence Unit (EIU), and a slow recovery is forecast with real GDP growth of 0.5% in 2010, rising to 2.3% in 2015.
The country has a long history of providing accessible healthcare, although resources are comparatively low for a Western European country. The government has introduced a mandatory health insurance scheme, which commenced in January 2006. This replaced the previous two-tier system and provides basic health insurance cover for acute care services with a separate scheme for long term medical care. The new health insurance act has substantially increased price competition amongst insurers and healthcare providers, resulting in one of the most market-oriented healthcare systems in Europe.
The Dutch pharmaceutical market is characterised by comparatively low per capita spending and a heavy reliance on generics. Drug consumption is nonetheless rising steadily in response to the growing healthcare needs of the ageing population. Although cost containment remains a priority, the reforms to the healthcare system implemented in 2006 also emphasise the need for accessible, quality care and the market is generally receptive to innovative products, which are one of the main growth drivers.
Generics now account for more than half the market by volume. However, generic revenues contracted in 2008 as a result of a price war between suppliers in response to health insurers implementing a preferential supplier policy.
Whilst pharmaceutical production is fairly modest, the Netherlands has long had a reputation for providing a sound base for clinical research. This has been accomplished by a close working relationship between companies and universities. Research is undertaken for third parties in university centres, government and private institutions.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and
The country has a long history of providing accessible healthcare, although resources are comparatively low for a Western European country. The government has introduced a mandatory health insurance scheme, which commenced in January 2006. This replaced the previous two-tier system and provides basic health insurance cover for acute care services with a separate scheme for long term medical care. The new health insurance act has substantially increased price competition amongst insurers and healthcare providers, resulting in one of the most market-oriented healthcare systems in Europe.
The Dutch pharmaceutical market is characterised by comparatively low per capita spending and a heavy reliance on generics. Drug consumption is nonetheless rising steadily in response to the growing healthcare needs of the ageing population. Although cost containment remains a priority, the reforms to the healthcare system implemented in 2006 also emphasise the need for accessible, quality care and the market is generally receptive to innovative products, which are one of the main growth drivers.
Generics now account for more than half the market by volume. However, generic revenues contracted in 2008 as a result of a price war between suppliers in response to health insurers implementing a preferential supplier policy.
Whilst pharmaceutical production is fairly modest, the Netherlands has long had a reputation for providing a sound base for clinical research. This has been accomplished by a close working relationship between companies and universities. Research is undertaken for third parties in university centres, government and private institutions.
Highly detailed report content
MARKET OUTLOOK
Key national data projections
Pharmaceutical Market Analysis
Current market size
Market structure
Unique 5-year market projections
Imports
Domestic manufacturing
Exports
Research & development
Pharmaceutical regulatory analysis
Including regulation, pricing & reimbursement and intellectual property
Pharmaceutical distribution
Healthcare analysis
Including demographics, healthcare system, health expenditure, healthcare infrastructure and personnel HEALTHCARE DATA
A comprehensive tabula review of the market, including economic indicators, demographics, health expenditure, hospital and primary care data, and